Company / R&D Expense
GERON CORP R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$103.7M
FY2024
5-year range
$13.4M / $125.0M
FY2020-FY2024
Trend
-17.0%
vs FY2023
Sector context
#141 of 210
Health Care
What the data says
At $104M, GERON CORP's r&d expense ranks #141 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $11M in FY2019 to $125M in FY2023.
Based on SEC 10-K filings.
$104M in FY2024 with a 5-year CAGR of +56.5%.
Improved from $96M to $104M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +25.8%
- 5-Year CAGR
- +56.5%
- 10-Year CAGR
- -
Sector benchmark
#141 of 210 in Health CareTop 67% of 210This company $103.7M Sector average $644.0M
▼
-83.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +56.5%, indicating consistent growth.
- In FY2024, r&d expense decreased 17.0% year-over-year.
- Ranks #141 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $103.7M | -17.0% |
| FY2023 | $125.0M | +30.9% |
| FY2022 | $95.5M | +83.4% |
| FY2021 | $52.1M | +287.7% |
| FY2020 | $13.4M | +21.7% |
| FY2019 | $11.0M | -38.9% |
| FY2018 | $18.0M | +1.2% |
| FY2017 | $17.8M | -13.9% |
| FY2016 | $20.7M | -10.6% |
| FY2015 | $23.2M | -54.9% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026